• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.

作者信息

Wan Marilyn T, Shin Daniel B, Winthrop Kevin L, Gelfand Joel M

机构信息

Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Division of Infectious Diseases and Public Health, Oregon Health and Sciences University, Portland, Oregon.

出版信息

J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.

DOI:10.1016/j.jaad.2020.05.035
PMID:32416207
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7235584/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82a7/7235584/ae28942c18b3/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82a7/7235584/cd9efc9def05/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82a7/7235584/ae28942c18b3/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82a7/7235584/cd9efc9def05/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/82a7/7235584/ae28942c18b3/gr2_lrg.jpg

相似文献

1
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.接受白细胞介素17通路抑制生物制剂治疗的银屑病患者发生呼吸道感染和症状的风险：对COVID-19大流行期间决策相关关键试验的荟萃估计。
J Am Acad Dermatol. 2020 Aug;83(2):677-679. doi: 10.1016/j.jaad.2020.05.035. Epub 2020 May 19.
2
The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.接受白细胞介素23通路抑制生物制剂治疗的银屑病患者发生呼吸道感染的风险：COVID-19大流行期间与决策相关的关键试验的荟萃估计。
J Am Acad Dermatol. 2020 Nov;83(5):1523-1526. doi: 10.1016/j.jaad.2020.06.1014. Epub 2020 Jul 2.
3
COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.新型冠状病毒肺炎与银屑病生物制剂：高流行地区的经验——意大利伦巴第大区贝加莫市
J Am Acad Dermatol. 2020 Jul;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165. Epub 2020 May 6.
4
Treatment discontinuation and rate of disease transmission in psoriasis patients receiving biologic therapy during the COVID-19 pandemic: A Canadian multicenter retrospective study.2019年冠状病毒病大流行期间接受生物治疗的银屑病患者的治疗中断情况及疾病传播率：一项加拿大多中心回顾性研究
J Am Acad Dermatol. 2020 Oct;83(4):1212-1214. doi: 10.1016/j.jaad.2020.07.021. Epub 2020 Jul 15.
5
Chronic inflammatory skin diseases and biologics: what to expect after COVID-19 pandemic?慢性炎症性皮肤病与生物制剂：新冠疫情大流行之后的展望？
Int J Dermatol. 2020 Sep;59(9):1144-1145. doi: 10.1111/ijd.15059. Epub 2020 Jul 25.
6
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.2019年冠状病毒病大流行对接受生物疗法治疗的慢性斑块状银屑病患者的影响：意大利北部的经验。
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
7
Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic.评估在2019冠状病毒病大流行期间使用度普利尤单抗治疗特应性皮炎的风险。
J Am Acad Dermatol. 2020 Sep;83(3):e251-e252. doi: 10.1016/j.jaad.2020.06.015. Epub 2020 Jun 10.
8
Clinical considerations for managing dermatology patients on systemic immunosuppressive or biologic therapy, or both, during the COVID-19 pandemic.在2019冠状病毒病大流行期间，对接受全身免疫抑制治疗或生物治疗或两者兼有的皮肤科患者进行管理的临床考量。
J Am Acad Dermatol. 2020 Jul;83(1):288-292. doi: 10.1016/j.jaad.2020.04.143. Epub 2020 May 4.
9
[Not Available].[无可用内容]
Rev Med Suisse. 2020 Jun 3;16(696):1174-1175.
10
Keeping track of the SARS-CoV-2 vaccine pipeline. 跟踪 SARS-CoV-2 疫苗研发管线。
Nat Rev Immunol. 2020 Nov;20(11):650. doi: 10.1038/s41577-020-00455-1.

引用本文的文献

1
Incidence of upper respiratory tract infections with biological therapies in moderate to severe atopic dermatitis: a systematic review and meta-analysis.中度至重度特应性皮炎生物治疗中呼吸道感染的发生率：一项系统评价和荟萃分析。
Front Med (Lausanne). 2025 Apr 2;12:1550640. doi: 10.3389/fmed.2025.1550640. eCollection 2025.
2
Management of Systemic Anti-psoriatic Drugs in Psoriasis Patients with Concurrent Paraplegia or Tetraplegia: Insights From a 6-Year Multicenter, Retrospective Observational Study.并发截瘫或四肢瘫的银屑病患者全身性抗银屑病药物的管理：一项为期6年的多中心回顾性观察研究的见解
Dermatol Ther (Heidelb). 2025 Feb;15(2):427-436. doi: 10.1007/s13555-025-01338-w. Epub 2025 Jan 24.
3

本文引用的文献

1
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?COVID-19：慢性炎症性疾病中细胞因子靶向治疗的风险？
Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.
2
Should biologics for psoriasis be interrupted in the era of COVID-19?在新冠疫情时代，银屑病生物制剂是否应中断使用？
J Am Acad Dermatol. 2020 May;82(5):1217-1218. doi: 10.1016/j.jaad.2020.03.031. Epub 2020 Mar 19.
3
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.美国皮肤病学会-银屑病基金会联合指南：生物制剂治疗银屑病的管理与治疗。
Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters.
斑块状银屑病加重与COVID-19疫苗接种：评估皮疹发作特征和暴露组参数
Vaccines (Basel). 2024 Feb 9;12(2):178. doi: 10.3390/vaccines12020178.
4
Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials.接受生物制剂和小分子疗法治疗银屑病和银屑病关节炎患者的感染及严重感染的短期比较风险：一项随机对照试验的系统评价和网状荟萃分析
Ther Adv Chronic Dis. 2023 Oct 27;14:20406223231206225. doi: 10.1177/20406223231206225. eCollection 2023.
5
Efficacy and Safety of Tildrakizumab in Older Patients: Pooled Analyses of Two Randomized Phase III Clinical Trials (reSURFACE 1 and reSURFACE 2) Through 244 Weeks.替西罗莫司在老年患者中的疗效和安全性：两项随机 III 期临床试验（reSURFACE 1 和 reSURFACE 2）的 244 周汇总分析。
Acta Derm Venereol. 2023 Oct 25;103:adv17752. doi: 10.2340/actadv.v103.17752.
6
The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.皮肤科疾病免疫调节治疗对感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）风险及与冠状病毒病（COVID-19）相关结局的影响
Curr Dermatol Rep. 2023;12(2):45-55. doi: 10.1007/s13671-023-00385-w. Epub 2023 Apr 3.
7
Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis.银屑病患者接受白细胞介素-17 抑制剂治疗后感染 COVID-19、住院和死亡的风险：系统评价和荟萃分析。
Front Immunol. 2022 Oct 21;13:1046352. doi: 10.3389/fimmu.2022.1046352. eCollection 2022.
8
Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis.呼吸道感染与 330 例中轴型脊柱关节炎或银屑病关节炎患者感染相关因素的队列研究。
Front Immunol. 2022 Oct 26;13:1040725. doi: 10.3389/fimmu.2022.1040725. eCollection 2022.
9
Immunogenicity of three doses of anti-SARS-CoV-2 BNT162b2 vaccine in psoriasis patients treated with biologics.在接受生物制剂治疗的银屑病患者中，三剂抗SARS-CoV-2 BNT162b2疫苗的免疫原性。
Front Med (Lausanne). 2022 Sep 6;9:961904. doi: 10.3389/fmed.2022.961904. eCollection 2022.
10
SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.SARS-CoV-2 疫苗接种与银屑病患者的实际问题：叙述性综述。
Dermatol Ther. 2022 May;35(5):e15430. doi: 10.1111/dth.15430. Epub 2022 Mar 22.
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.
4
Yin and yang of interleukin-17 in host immunity to infection.白细胞介素-17在宿主抗感染免疫中的阴阳两面。
F1000Res. 2017 May 23;6:741. doi: 10.12688/f1000research.10862.1. eCollection 2017.